{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:41:44Z","timestamp":1767984104547,"version":"3.49.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Maintenance therapy could significantly improve the prognosis of patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Anlotinib is effective, tolerable, and convenient in administration as a third-line treatment for NSCLC. This study aimed to evaluate the efficacy and safety of maintenance therapy with anlotinib after platinum-based induction chemotherapy for patients with advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This pooled analysis of 2 multicenter, open-label, single-arm, phase 2 clinical trials (ALTER-L014 and ALTER-L011) enrolled patients with locally advanced or metastatic NSCLC and without known sensitive mutations in China between September 2018 and January 2021. The primary outcome was progression-free survival. The secondary outcomes were objective response rate, disease control rate, overall survival, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The data of 23 patients were pooled, with 15 from ALTER-L014 and 8 from ALTER-L011. At the cutoff date of June 13, 2021, the median progression-free survival since the start of maintenance therapy was 5.95 (95% confidence interval, 4.30\u20138.80) months. Nineteen patients had stable disease, 1 had a partial response and 3 had progressive disease. The objective response rate was 4.35%, while disease control rate was 86.96%. The median overall survival of the patients since the start of maintenance therapy was 18.60 (95% confidence interval, 6.87\u201322.80) months. The incidence of adverse events of grade\u2005\u2265\u20053 was 21.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Anlotinib might offer a new option for maintenance treatment in patients with locally advanced or metastatic NSCLC without known sensitive mutations after standard first-line platinum-based chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000038459","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:03:51Z","timestamp":1720195431000},"page":"e38459","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials"],"prefix":"10.1097","volume":"103","author":[{"given":"Yiqian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyun","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medicine School, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Respiratory, Zhongda Hospital, Southeast University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medicine School, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huai\u2019an First Hospital Affiliated to Nanjing Medical University, Huai\u2019an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yancheng First Hospital Affliated to Nanjing University Medicine School, Yancheng, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengbin","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Taizhou People\u2019s Hospital Affiliated to Nanjing Medical University, Taizhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziling","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kewei","family":"Ma","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanya","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuguang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naifei","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rilan","family":"Bai","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-7550","authenticated-orcid":false,"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 4","key":"R1-20260109","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"issue":"16_Suppl","key":"R2-20260109","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2022.40.16_suppl.4073","article-title":"Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): a prospective, single-arm phase II trial.","volume":"40","author":"Liu","year":"2022","journal-title":"J Clin Oncol"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.3390\/cancers13184543","article-title":"NSCLC biomarkers to predict response to Immunotherapy with Checkpoint Inhibitors (ICI): from the cells to in vivo images.","volume":"13","author":"Liberini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"e000550","DOI":"10.1136\/jitc-2020-000550","article-title":"Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.","volume":"8","author":"He","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study.","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","article-title":"Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.","volume":"30","author":"P\u00e9rol","year":"2012","journal-title":"J Clin Oncol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","article-title":"Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).","volume":"31","author":"Barlesi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.19.01006","article-title":"Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer: ECOG-ACRIN 5508.","volume":"37","author":"Ramalingam","year":"2019","journal-title":"J Clin Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R14-20260109","first-page":"36","article-title":"China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.","volume":"39","author":"Zhou","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: first global approval.","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).","volume":"118","author":"Han","year":"2018","journal-title":"Br J Cancer"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"575","DOI":"10.21037\/tlcr.2019.09.21","article-title":"The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial.","volume":"8","author":"Wang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"e25709","DOI":"10.1097\/MD.0000000000025709","article-title":"Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: a systemic review and meta-analysis of its efficacy and safety.","volume":"100","author":"Ye","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","article-title":"Eighth edition of the UICC classification of malignant tumours: an overview of the changes in the pathological TNM classification criteria-what has changed and why?","volume":"472","author":"Bertero","year":"2018","journal-title":"Virchows Arch"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.lungcan.2014.12.014","article-title":"Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.","volume":"87","author":"Tong","year":"2015","journal-title":"Lung Cancer"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"102820","DOI":"10.1016\/j.critrevonc.2019.102820","article-title":"Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives.","volume":"146","author":"Rebuzzi","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"338","DOI":"10.21037\/atm-20-8078","article-title":"Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial.","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"e26862","DOI":"10.1097\/MD.0000000000026862","article-title":"Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis.","volume":"100","author":"Kong","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jcpt.13534","article-title":"The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab\/pemetrexed alone for stage IIIB\/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials.","volume":"47","author":"Liu","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/CMAR.S148009","article-title":"Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.","volume":"10","author":"Shafique","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12885-022-09674-2","article-title":"Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.","volume":"22","author":"Gu","year":"2022","journal-title":"BMC Cancer"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/imt-2022-0166","article-title":"Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA.","volume":"15","author":"Aggarwal","year":"2023","journal-title":"Immunotherapy"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial.","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: a multicenter phase 2 trial.","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2015.04.026","article-title":"Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).","volume":"51","author":"O\u2019Brien","year":"2015","journal-title":"Eur J Cancer"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-07-4544","article-title":"Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.","volume":"14","author":"Zhou","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer.","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","article-title":"Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.","volume":"25","author":"Barlesi","year":"2014","journal-title":"Ann Oncol"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00432-021-03752-x","article-title":"The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.","volume":"148","author":"Wang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/JTO.0b013e3182a46bcf","article-title":"Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).","volume":"8","author":"Rittmeyer","year":"2013","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:04:50Z","timestamp":1767967490000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":41,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038459","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}